Adverse drug events (ADEs) are a serious health issue in the United States. About 82% of American adults take at least one medication while 29% take five or more. ADEs lead to 700,000 emergency room visits, 120,000 hospitalizations and 100,000 deaths in the US each year. This results in over $30 billion in additional spend annually. 1

Pharmacogenomics studies have shown that more than 50% of the patient population are dosing ineffectively due at least in part to a genetic mismatch between the patient’s metabolism and the medication. Recent genetic research has helped to create a better understanding of this mismatch by explaining the significance of genetics in drug metabolism.

This information about a patient’s genetic makeup, coupled with their lifestyle behavior and other risk factors, enhances the physician’s ability to provide personalized medical care and treatment to each patient.

culture layer

PGX AdvantageTM
Pharmacogenomics Testing

At AEON, we are committed to increasing awareness, understanding, and clinical use of pharmacogenomics testing. Our 17 gene PGX Advantage testing profile provides information about the connection between a patient’s unique genetic makeup and their response to certain cardiology, pain and psychiatry medications.

We understand that as physicians, you must continually seek out ways to enhance the care you provide to each of your patients. Our pharmacogenomics tests provide information that enable you to offer personalized care and tailored medication to meet your patient’s unique needs with positive outcomes.

Who can Benefit from Pharmacogenomics Testing?

Pharmacogenomics testing can improve outcomes for patients, reduce costs for payors, and enhance the overall quality of care delivered by the physician. These tests can reduce the number of failed drug treatments, adverse drug reactions, the number of medications a patient takes before finding the right one, and provide a more complete clinical picture of each patient.

Patients who can benefit from PGX testing include those:

  • taking multiple medications
  • on complex drug treatment plans
  • with current prescriptions that are not working
  • and with previous adverse drug reactions (ADRs) to medications


Broad Testing Profile

Broad Testing Profile

Our broad testing profile provides information for physicians to identify a patient as a slow, intermediate, fast, or ultra-fast metabolizer of over 200 different drugs across 30 different drug classes. Our Comprehensive Pharmacogenomics Profile includes genetic-metabolic relationships for antifungal, antiemetic, acid disorder, immunosuppressant and urinary incontinence medications. Risk factors for thrombophilia, hyperhomocysteinemia and dyslipidemia are also tested.

Safer and More Effective Treatment

Safer and More Effective Treatment

We help physicians maximize drug efficacy while minimizing adverse drug effects and drug to drug interactions. We provide you with information that allows you to prescribe the right drug at the correct dosage based on an individual’s genotype as well as their weight and age.

Use of Latest Technology

Use of Latest Technology

We use state-of-the-art, high-throughout genotyping technology to analyze patient samples that ensures speed and accuracy of results. Our fully equipped, next generation laboratories have the capability to handle large volumes and capacity for growth.

Effective Quality Controls

Effective Quality Controls

Ensuring accuracy and speed, we employ robotic testing systems for precision: each step is automated to avoid human error. This approach enables AEON to provide fast and reliable turnaround times. At AEON, every test result is reviewed at least twice while the final report is reviewed by a senior scientist before being released. Every patient sample is run twice to deliver double the industry standards.

Well-Trained Scientists

Highly Trained Scientists

Our experienced management team and Ph.D. scientists position us well to achieve better results and improved performance. All pharmacogenetic patient samples are handled with the greatest care by highly trained genetic scientists in our state-of-the-art facility. The scientists are also available for in-depth consultations. AEON also has a strong, internationally renowned, cross-functional scientific advisory board that positions us as a leading player in scientific innovation in the areas of clinical diagnostics and healthcare technology.

Easily Interpreted and Clinically Actionable Reports

Easily Interpreted and Clinically Actionable Reports

Our testing reports are comprehensive and easy-to-understand; in each testing protocol the outcomes are produced in simple formats delivered via a secured portal, fax or EMR. AEON also provides professional assistance in the interpretation of results; trained genetic scientists are on-hand to help physicians understand the results and integrate them into a patient’s overall treatment plan.

Exceptional Customer Service

We know that our work impacts the lives of people. We focus on providing exceptional customer service by providing our partner healthcare professionals with customized service plans to maximize the effective delivery of care for patients.

The Testing Process

Impacted Medications and Genes Tested*

Impacted Medications and Genes Tested


1 National Center for Complementary and Integrative Health (NCCIH) and the Centers for Disease Control and Prevention (CDC), based on data from a special supplement—on use of complementary health approaches—to the 2012 National Health Interview Survey (NHIS).